bempedoic acid/ezetimibe vs cholestyramine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of bempedoic acid/ezetimibe and cholestyramine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Cholestyramine Clinical Impact: Concomitant use of NEXLIZET and cholestyramine decreases ezetimibe concentration. Intervention: Administer NEXLIZET either at least 2 hours before or at least 4 hours after bile acid sequestrants [see Dosage and Administration (2.2) ] .
Nexlizet
Questran
Nexlizet is a combination medicine that helps lower cholesterol. It is used with diet and exercise to lower LDL-C (bad cholesterol) in adults.
Cholestyramine is a medicine that helps lower high cholesterol levels in your blood. It works by preventing your body from absorbing cholesterol in the intestines.
Nexlizet is used to lower LDL-C (bad cholesterol) in adults who have high cholesterol. This includes people with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). One of the medicines in Nexlizet can also lower the risk of heart problems like heart attack and stroke in adults who are at high risk and cannot take statins.
This medicine is used with a diet to lower high cholesterol, especially LDL cholesterol (the "bad" cholesterol). It may also help if you have high triglycerides, but it's not the best choice if high triglycerides are your main problem. Lowering cholesterol helps reduce your risk of heart disease.
Nexlizet contains two medicines that work in different ways to lower cholesterol. Bempedoic acid blocks an enzyme in your liver that makes cholesterol. Ezetimibe stops your body from absorbing cholesterol from food.
Cholestyramine is a resin that binds to bile acids in your intestines. Bile acids help digest fats, including cholesterol. By binding to bile acids, cholestyramine prevents them from being reabsorbed, so your body uses cholesterol to make more bile acids, which lowers cholesterol levels in your blood.
- • Upper respiratory tract infection (like a cold)
- • Muscle spasms
- • High uric acid levels in the blood
- • Back pain
- • Stomach pain or discomfort
- • Constipation
- Muscle pain 53
- Joint pain 51
- Pain in your arms or legs 40
- Muscle spasms 32
- Tiredness 30
- Diarrhoea 1,631
- Fatigue 877
- Nausea 783
- Arthralgia 621
- Headache 543
This medicine can raise uric acid levels in your blood, which can cause gout. Tell your doctor if you have symptoms of high uric acid, like joint pain or swelling. Nexlizet can also increase your risk of tendon rupture. Stop taking Nexlizet and call your doctor right away if you have tendon pain, swelling, or difficulty moving.
Since cholestyramine can affect how your body absorbs other medicines, take other drugs at least 1 hour before or 4 to 6 hours after taking cholestyramine.
This medicine may harm your unborn baby. Do not take Nexlizet if you are pregnant or planning to become pregnant. Talk to your doctor about other ways to lower your cholesterol during pregnancy.
Tell your doctor if you are pregnant or plan to become pregnant. Cholestyramine may affect how you absorb vitamins, so your doctor may recommend supplements. Talk to your doctor about the risks and benefits of taking this medicine while breastfeeding.
Also Compare, Nearby Drugs
Compare cholestyramine with
How to Read This bempedoic acid/ezetimibe vs cholestyramine Comparison
bempedoic acid/ezetimibe is classified in the ACL Inhibitor / Cholesterol Absorption Inhibitor drug class, while cholestyramine sits within the Bile Acid Sequestrant class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bempedoic acid/ezetimibe has 206 submissions while cholestyramine has 4,455. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to cholestyramine can bind to the other medicine, which prevents your body from absorbing it correctly.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bempedoic acid/ezetimibe or cholestyramine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.